Hyatt Regency Boston1 Avenue de LafayetteBoston, MA 02111United States,

Boston,

MA,

US,

ZIP: 02111

Phone:

Stem Cell Summit

 

*** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! ***
REGISTER TODAY!

 

 

GTCbio is proud to present the Stem Cell Summit 2021, to be held in San Diego, CA. The Stem Cell Summit provides information on cutting-edge developments in all areas of stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development, and the commercialization of stem cells. This summit comprises of presentations, panels and round-table discussions to highlight pre-clinical and clinical studies in regenerative medicine, immunotherapy, stem cell reprogramming, cell therapy in diabetes, regulatory policies regarding stem cell research, manufacturing and other relevant topics.

Stem Cell Summit 2021 includes two back-to-back conferences including joint plenary session:

Conference 1: 15th Stem Cell Research & Regenerative Medicine

1. Advances in Adult & Pluripotent Stem Cell Research

2. Revolution in Immunotherapy

3. What’s in the Pipeline: Pre-clinical & Clinical Strategies

Joint: Plenary Session

1. Where do We Stand with Cell Therapy in Diabetes?

Conference 2: 7th Stem Cell Product Development & Commercialization

1. Regulatory Challenges in Cell Therapy

2. Funding and Partnering

3. Stem Cells for Drug Discovery & Disease Modeling

4. Manufacturing and Scalable Processes

5. Biotech Showcase: Emerging Pipelines

6. Commercialization: Creating Sustainable Business Models

 

 

AGENDA

Day 1 - Thursday, April 12, 2021

7:30 Continental Breakfast & Registration
8:15 Opening Remarks by GTCbio
Opening Keynote Session – Historical Perspective and State of the Science & Industry

KEYNOTE
8:30Stem Cells for Diabetics
Douglas Melton Douglas Melton 
Professor
Harvard University

Abstract: The advances and remaining challenges...Read More 
KEYNOTE
9:15Clinical and Commercial Application of Scaled Human Stem Cell Derivates
Hans Keirstead Hans Keirstead 
Chief Executive Officer
AIVITA Biomedical

Abstract: AIVITA Biomedical has developed propr...Read More 
10:00 Morning Networking Break
Stem Cell Product Development & Commercialization
Stem Cells for Drug Discovery & Disease Modeling 
Moderator: Scott Olson, University of Texas 
10:30Stem Cell Derived Human-on-a-chip Systems for Use in Efficacy and Toxicological Investigations in Pre-clinical Drug Discovery
James Hickman James Hickman 
Professor, NanoScience Technology Center
University of Central Florida

Abstract: The utilization of human-on-a-chip or...Read More 
Stem Cell Research & Regenerative Medicine
Advances in Adult Stem Cell Research

10:30Addressing Age-related Macular Degeneration with Adult Retinal Pigment Epithelial Stem Cells
Sally Temple Sally Temple 
Scientific Director
Neural Stem Cell Institute

Abstract: The retinal pigment epithelium (RPE) ...Read More 
10:55Ensuring the quality of stem cell derived models for toxicity testing. In: Validation of Alternative Methods for Toxicity Testing.
Glyn Stacey Glyn Stacey 
Head of Division
National Institute for Biological Standards and Control

Abstract: The development of in vitro assays fo...Read More 
10:55
Douglas Losordo Douglas Losordo 
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences

11:20Medical Gas Therapy for SCI: Roles of Adult Neurogenesis
Yang (Ted) D Teng Yang (Ted) D Teng 
Director, Laboratory of SCI, Stem Cell & Neurofacilitation Research PM&R and Neurosurgery
Harvard University and Spaulding Rehabilitation Hospital

Abstract: We previously reported that non-toxic...Read More 
11:20Bone Marrow Cells for Heart Repair: Cumulative Clinical Evidence and Insights
Buddhadeb Dawn Buddhadeb Dawn 
Director, Midwest Stem Cell Therapy Center 
University of Kansas Medical Center

Abstract: Numerous clinical trials of bone marr...Read More 
11:45
TBA (To Be Announced) TBA (To Be Announced)

11:45
Silviu Itescu Silviu Itescu 
Chief Executive Officer & Managing Director
Mesoblast

12:10 Lunch on Your Own
Stem Cell Product Development & Commercialization
Partnering between Industry, Academia, and CROs to Advance Research

1:45Cross-institutional Collaboration in Academia and Industry
Brock Reeve Brock Reeve 
Executive Director
Harvard Stem Cell Institute

Stem Cell Research & Regenerative Medicine
Advances in Pluripotent Stem Cell Research

1:45
Mahendra Rao Mahendra Rao 
Vice President for Regenerative Medicine
New York Stem Cell Foundation

2:10
Anthony Ting Anthony Ting 
Vice President
Athersys

2:10
Kristin Baldwin Kristin Baldwin 
Professor, Investigator, Dorris Neuroscience Center, Department of Neuroscience California Campus
Scripps Institute

2:35Panel Discussion: Partnering between Industry, Academia, and CROs to Advance Research
Panelist:Alain Vertès Alain Vertès 
Managing Director
NxR Biotechnologies GmbH
Panelist:TBA (To Be Announced) TBA (To Be Announced)

Panelist:TBA (To Be Announced) TBA (To Be Announced)

2:35
Kevin Eggan Kevin Eggan 
Professor in the Department of Stem Cell and Regenerative Biology
Harvard University

3:00
TBA (To Be Announced) TBA (To Be Announced)

3:25 Afternoon Networking Break
Round Table Sessions 
5:15 Networking Reception & Poster Session
Day 1 Day 2
 

 

Day - 2 Friday, April 13, 2021

7:15 Breakfast with Mentors from Academia & Industry (RSVP Only)
7:30 Continental Breakfast for All Attendees
Stem Cell Product Development & Commercialization
Manufacturing and Scalable Processes for Cell Therapy

8:30
Katy Spink Katy Spink 
Managing Partner
Dark Horse Consulting

Stem Cell Research & Regenerative Medicine
Translation to the Clinic: What’s in the Pipeline

8:30Mesenchymal Stromal Cells – Pre-clinical Science, Clinical Development and Pathway to Marketing Approval
Jacques Galipeau Jacques Galipeau 
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison

Abstract: Mesenchymal Stromal Cells have been t...Read More 
8:55
Emily Titus Emily Titus 
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)

8:55
Deborah Ascheim Deborah Ascheim 
Chief Medical Officer 
Capricor

9:20Efficient Scale Up/Scale Out of Cell Therapies
Kevin Murray Kevin Murray 
Vice President, Global Sales
BioSpherix Medical

Abstract: The first cell therapies have finally...Read More 
9:20Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy
Bob Valamehr Bob Valamehr 
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.

Abstract: The unique attributes of a combinator...Read More 
9:45Cell Therapy Manufacturing, a Continuous Development
Wilfried Dalemans Wilfried Dalemans 
Chief Technical Officer
Tigenix

Abstract: Cell therapy manufacturing starts alr...Read More 
9:45Clinical Trials in TBI: Preventing the Next Failure
Scott Olson Scott Olson 
Assistant Professor, Program in Regenerative Medicine 
University of Texas

Abstract: Clinical trials using small molecules...Read More 
10:10 Morning Networking Break
Stem Cell Product Development & Commercialization
Funding & Commercialization of Cell Therapy

10:40Accelerating Stem Cell Therapy Development
Gil Sambrano Gil Sambrano 
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine

Abstract: The California Institute for Regenera...Read More 
Stem Cell Research & Regenerative Medicine
Revolution in Immunotherapy

10:40
Khalid Shah Khalid Shah 
Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School

11:05
Patrick Keenan Patrick Keenan 
Managing Director
Prevail Partners

11:05
Richard Morgan Richard Morgan 
Vice President, Immunotherapy
Bluebird Bio

11:30Panel: Funding & Commercialization of Cell Therapy
Panelist:Gail Naughton Gail Naughton 
Chief Executive Officer
Histogen
Panelist:Michael May Michael May 
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)
Panelist:Gregory Bonfiglio Gregory Bonfiglio 
Managing Partner
Proteus Venture Partners
11:30IMPACT: Re-engineered CAR19 T cells have Potent Activity Against Hematologic and Solid Tumors
Paul Rennert Paul Rennert 
President & CSO
Aleta Biotherapeutics

Abstract: CAR-CD19 T cell therapeutics are appr...Read More 
11:55
MyLinh Duong MyLinh Duong 
Senior Scientist
Bellicum Pharmaceuticalsss

Lunch Session: Regulatory Challenges in Cell Therapy

12:30Japanese Policy for Regulatory Science of Stem Cell Therapies
Toshio Miyata Toshio Miyata 
Professor, Office for Industry-University Co-Creation
Osaka University

Abstract: Japan government fosters pharmaceutic...Read More 
12:55Global Regulatory Policy and Project Update
Melody Eble Melody Eble 
Director, Global Regulatory Affairs
Janssen Research & Development, LLC

Abstract: This session will describe select, re...Read More 
Award Ceremony & Closing Keynote Lunch Session

KEYNOTE
1:20
Evan Snyder Evan Y. Snyder 
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute

KEYNOTE
2:05A Glimpse of the Next 10 Years for Pluripotent Stem Cell-based Therapies
Erin Kimbrel Erin Kimbrel 
Senior Director of Development
Astellas Institute for Regenerative Medicine

Keynote Panel Discussion 
Moderator: Erin Kimbrel, Astellas Institute for Regenerative Medicine 
2:20
Moderator:
Erin Kimbrel Erin Kimbrel 
Senior Director of Development
Astellas Institute for Regenerative Medicine
Panelist:
Evan Snyder Evan Y. Snyder 
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute
Panelist:
Hans Keirstead Hans Keirstead 
Chief Executive Officer
AIVITA Biomedical
3:05 Summit Concludes

 

 

 

SPEAKER

PLENARY KEYNOTE SPEAKERS

Hans Keirstead 
Chief Executive Officer
AIVITA Biomedical


Erin Kimbrel 
Senior Director of Development
Astellas Institute for Regenerative Medicine


Douglas Melton 
Professor
Harvard University


Evan Y. Snyder 
Professor and Director, Program in Stem Cell & Regenerative Biology
Sanford-Burnham Medical Research Institute

PLENARY SPEAKERS

Melody Eble 
Director, Global Regulatory Affairs
Janssen Research & Development, LLC


Toshio Miyata 
Professor, Office for Industry-University Co-Creation
Osaka University

Stem Cell Product Development & Commercialization
DISTINGUISHED SPEAKERS

Gregory Bonfiglio 
Managing Partner
Proteus Venture Partners


Wilfried Dalemans 
Chief Technical Officer
Tigenix


Matthew Durdy 
Chief Business Officer
Cell Therapy Catapult


James Hickman 
Professor, NanoScience Technology Center
University of Central Florida


Patrick Keenan 
Managing Director
Prevail Partners


Kevin Murray 
Vice President, Global Sales
BioSpherix Medical


Gail Naughton 
Chief Executive Officer
Histogen


Brock Reeve 
Executive Director
Harvard Stem Cell Institute


Gil Sambrano 
Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine


Katy Spink 
Managing Partner
Dark Horse Consulting


Glyn Stacey 
Head of Division
National Institute for Biological Standards and Control


Emily Titus 
Director, Technology Development
Centre for Commercialization of Regenerative Medicine (CCRM)


Alain Vertès 
Managing Director
NxR Biotechnologies GmbH

Stem Cell Research & Regenerative Medicine
DISTINGUISHED SPEAKERS

Scott Olson 
Assistant Professor, Program in Regenerative Medicine 
University of Texas


Deborah Ascheim 
Chief Medical Officer 
Capricor


Kristin Baldwin 
Professor, Investigator, Dorris Neuroscience Center, Department of Neuroscience California Campus
Scripps Institute


Buddhadeb Dawn 
Director, Midwest Stem Cell Therapy Center 
University of Kansas Medical Center


MyLinh Duong 
Senior Scientist
Bellicum Pharmaceuticalsss


Kevin Eggan 
Professor in the Department of Stem Cell and Regenerative Biology
Harvard University


Jacques Galipeau 
Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy
University of Wisconsin in Madison


Silviu Itescu 
Chief Executive Officer & Managing Director
Mesoblast


Chaim Lebovits 
President and CEO
Brainstorm Cell Therapeutics


Douglas Losordo 
Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs
Caladrius Biosciences


Marcela Maus 
Assistant Professor of Medicine; Director of Cellular Immunotherapy
Harvard Medical School; Cancer Center, Massachusetts General Hospital


Michael May 
President & CEO
Centre for Commercialization of Regenerative Medicine (CCRM)


Richard Morgan 
Vice President, Immunotherapy
Bluebird Bio


Mahendra Rao 
Vice President for Regenerative Medicine
New York Stem Cell Foundation


Paul Rennert 
President & CSO
Aleta Biotherapeutics


Khalid Shah 
Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School


Sally Temple 
Scientific Director
Neural Stem Cell Institute


Anthony Ting 
Vice President
Athersys


Bob Valamehr 
Vice President, Cancer Immunotherapy & Reprogramming Biology
Fate Therapeutics Inc.

 

 

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for: 
- Multiple participant discounts 
- Price quotations or visa invitation letters 
- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc) 
- Event sponsorship 

NO REFUNDS ALLOWED ON REGISTRATIONS 
Prices may go up any time. Service fees included in pricing. 
----------------------------------------------------------------- 
This event is brought to you by: 
Global Technology Community LLC - NewYorkEventsList 
http://www.NyEventsList.com 
http://www.BostonEventsList.com 
http://www.SFBayEventsList.com 
-----------------------------------------------------------------
MYL170816CEV MAR170927UPT MYL171025UPD

CHA171109UPT MAR20211124REV VIO180228UPD

MYL180302UPD JOA180315CEV